Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vera Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 4 Lin Celia (Chief Medical Officer) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Sold 1,490 shares @ $16.6547, valued at $24.8k
08/23/2023 4 Curley Joanne (Chief Development Officer) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Sold 1,490 shares @ $16.6558, valued at $24.8k
08/23/2023 4 Fordyce Marshall (President and CEO) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Sold 5,210 shares @ $16.6562, valued at $86.8k
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 16,231 $ 10,112 $ 41,340 $ 22,661 General and administrative 5,739 4,945 11,887 9,417 Total operating expenses 21,970 15,057 53,227 32,078 Loss from operations Total other income, net 1,808 204 2,996 140 Net loss $ $ $ $ Other comprehensive gain 82 Comprehensive loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 44,269,772 27,078,450 40,986,907 25,660,742 VERA THERAPEUTICS, INC. Condensed Balance Sheets June 30, December 31, 2023..."
08/02/2023 SC 13D/A Carlyle Group Inc. reports a 4.2% stake in Vera Therapeutics, Inc.
07/06/2023 4 Young Joseph R (SVP, Finance, Chief Acct Offcr) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Exercised 10,000 options to buy @ $3.9396, valued at $39.4k
07/05/2023 SC 13D/A Carlyle Group Inc. reports a 5.5% stake in Vera Therapeutics, Inc.
05/12/2023 4 SEIDENBERG BETH C (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Granted 20,000 options to buy @ $7.7, valued at $154k
05/12/2023 4 MORRISSEY MICHAEL (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Granted 20,000 options to buy @ $7.7, valued at $154k
05/12/2023 4 Morrison Scott W (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Granted 20,000 options to buy @ $7.7, valued at $154k
05/12/2023 4 Katabi Maha (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Granted 20,000 options to buy @ $7.7, valued at $154k
05/12/2023 4 Hall Kimball (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Granted 20,000 options to buy @ $7.7, valued at $154k
05/12/2023 4 ENRIGHT PATRICK G (10% Owner) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Granted 20,000 options to buy @ $7.7, valued at $154k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "VERA THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 25,108 $ 12,549 General and administrative 6,150 4,472 Total operating expenses 31,258 17,021 Loss from operations Total other income , net 1,189 Net loss $ $ Other comprehensive gain $ 220 $ Comprehensive loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 37,667,566 24,227,282 VERA THERAPEUTICS, INC. Condensed Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and short-term marketable securities $ 197,153 $ 114,653 Prepaid expense..."
04/13/2023 SC 13D/A Carlyle Group Inc. reports a 6.7% stake in Vera Therapeutics, Inc.
04/03/2023 4 SEIDENBERG BETH C (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Bought 2,300 shares @ $7.2395, valued at $16.7k
03/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/28/2023 8-K Quarterly results
03/21/2023 4 SEIDENBERG BETH C (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Bought 74,045 shares @ $7.1157, valued at $526.9k
Bought 15,252 shares @ $7.2143, valued at $110k
03/17/2023 4 SEIDENBERG BETH C (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Bought 32,844 shares @ $7.1249, valued at $234k
Bought 60,097 shares @ $7.093, valued at $426.3k
03/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/07/2023 4 SEIDENBERG BETH C (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Bought 1,000 shares @ $7.245, valued at $7.2k
02/27/2023 4 SEIDENBERG BETH C (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Bought 200 shares @ $7.235, valued at $1.4k
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in VERA THERAPEUTICS, INC.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/10/2023 SC 13G Kynam Capital Management, LP reports a 5.1% stake in Vera Therapeutics, Inc.
02/09/2023 4 SEIDENBERG BETH C (Director) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Bought 46,163 shares @ $7.24, valued at $334.2k
Bought 131,602 shares @ $7.03, valued at $925.2k
Bought 87,956 shares @ $7.08, valued at $622.7k
Bought 45,357 shares @ $7.22, valued at $327.5k
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in VERA THERAPEUTICS INC
02/08/2023 4 Longitude Capital Partners IV, LLC (10% Owner) has filed a Form 4 on Vera Therapeutics, Inc.
Txns: Bought 1,714,285 shares @ $7, valued at $12M
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy